Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey

被引：0
|
作者：
Bianchi, Gerolamo [1 ]
Carletto, Antonio [2 ]
Epis, Oscar M. [3 ]
Scioscia, Crescenzio [4 ]
Semeraro, Angelo [5 ]
Donati, Chiara [6 ]
Bazzichi, Laura [7 ]
Lapadula, Giovanni [8 ]
Sinigaglia, Luigi [9 ]
Lo Monaco, Andrea [10 ]
机构：
[1] Osped La Colletta, Div Reumatol, Genoa, Italy
[2] Univ Verona, Rheumatol Unit, I-37100 Verona, Italy
[3] AO Osped Niguarda Ca Granda, Rheumatol Unit, Milan, Italy
[4] Univ Bari Aldo Moro, DIM Sez Reuamtol, Bari, Italy
[5] ASL Taranto, Unita Operat Reumatol, Taranto, Italy
[6] Roche SpA, Monza, Italy
[7] Univ Pisa, Div Reumatol, Pisa, Italy
[8] Univ Bari, DIMIMP Rheumatol Unit, Bari, Italy
[9] IOG Pini, Rheumatol Dept, Milan, Italy
[10] Osped S Anna Ferrara, Ferrara, Italy
来源：
ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
498
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
    Abuhelwa, Ahmad Y.
    Hopkins, Ashley M.
    Sorich, Michael J.
    Proudman, Susanna
    Foster, David J. R.
    Wiese, Michael D.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [32] Outcomes with Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in Older Patients Treated for Rheumatoid Arthritis
    Akter, Ripa
    Maksymowych, Walter P.
    Martin, M. Liam
    Hogan, David B.
    CANADIAN GERIATRICS JOURNAL, 2020, 23 (02) : 184 - 189
  • [33] Adverse drug reactions associated with the use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
    Enrique Machado-Alba, Jorge
    Felipe Ruiz, Andres
    Enrique Machado-Duque, Manuel
    REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH, 2014, 36 (06): : 396 - 401
  • [34] Can Disease-Modifying Anti-Rheumatic Drugs Reduce the Risk of Developing Dementia in Patients with Rheumatoid Arthritis?
    Huang, Ling-Chun
    Chang, Yu-Han
    Yang, Yuan-Han
    NEUROTHERAPEUTICS, 2019, 16 (03) : 703 - 709
  • [35] Can Disease-Modifying Anti-Rheumatic Drugs Reduce the Risk of Developing Dementia in Patients with Rheumatoid Arthritis?
    Ling-Chun Huang
    Yu-Han Chang
    Yuan-Han Yang
    Neurotherapeutics, 2019, 16 : 703 - 709
  • [36] EVALUATION OF MEDICATION PERSISTENCE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH NON-TNFI DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    Ferri, Leticia
    Alemao, Evo
    Lama, Sonie
    Rao, Aarti
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1107 - 1108
  • [37] THE EFFECT OF BIOLOGICAL AND CONVENTIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS ON FATIGUE IN FIBROMYALGIC RHEUMATOID ARTHRITIS PATIENTS
    Hizmetli, S.
    Durmaz, Y.
    Kaptanoglu, E.
    Cengiz, A. K.
    Peksen, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 864 - 864
  • [38] Comment on: Lipid screening and statins alongside disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis
    Garton, Mark
    McInnes, Iain B.
    Sattar, Naveed
    RHEUMATOLOGY, 2020, 59 (02) : 453 - 454
  • [39] Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis
    Kurata, Izumi
    Tsuboi, Hiroto
    Terasaki, Mayu
    Shimizu, Masaru
    Toko, Hirofumi
    Honda, Fumika
    Ohyama, Ayako
    Yagishita, Mizuki
    Osada, Atsumu
    Ebe, Hiroshi
    Kawaguchi, Hoshimi
    Takahashi, Hiroyuki
    Hagiwara, Shinya
    Asashima, Hiromitsu
    Kondo, Yuya
    Matsumoto, Isao
    Sumida, Takayuki
    INTERNAL MEDICINE, 2019, 58 (12) : 1703 - 1712
  • [40] Pharmacogenetics of disease-modifying anti-rheumatic drugs
    Tanaka, E
    Taniguchi, A
    Urano, W
    Yamanaka, H
    Kamatani, N
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2004, 18 (02): : 233 - 247
12345